(Q44959249)

English

Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

ChEBI release 2020-05-28

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Kazunori Honda

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Noboru Yamamoto

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Hiroshi Nokihara

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Yosuke Tamura

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Hajime Asahina

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Yasuhide Yamada

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Shigenobu Suzuki

7

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Naoya Yamazaki

8

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Yoshitaka Ogita

9

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Tomohide Tamura

10

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

577-584

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

The GTPase superfamily: a conserved switch for diverse cell functions

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

The GTPase superfamily: conserved structure and molecular mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Ocular toxicity of targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2228-4

21 January 2018

Identifiers

10.1007/S00280-013-2228-4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44959249&oldid=2207011286"